GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes and platelets. GARP regulates the availability of membrane-bound latent TGF-β and modulates its activation. The function of GARP has been extensively studied on regulatory T lymphocytes (Tregs), where it complexes with αVβ8 integrins to release active TGF-β from the surface of the cells. Via this function, GARP was shown to be involved in enhancing the suppressive phenotype of Tregs and in maintaining Treg-mediated peripheral tolerance. A strong connection between GARP and cancer by describing the pro-tumorigenic function of this protein in several human malignancies and the unexpected role of platelet GARP in immune evasion and the cancer progression. Moreover, GARP expression has been recently described on human B cells in response to B cell receptor activation and Toll-like receptor (TLR) 9 ligation. Several drugs against GARP are also in development or in clinical trials. Thus, there is a need for pre-clinical models to evaluate the safety and efficacy of GARP-targeted therapeutics before they enter human trials. Biocytogen has generated a humanized GARP mouse for in vitro functional and in vivo efficacy evaluation of GARP antagonists.
Protein expression analysis in Treg cells
Strain specific GARP expression analysis in heterozygous B-hGARP mice by flow cytometry. Splenocytes were collected from WT and heterozygous B-hGARP (H/+) mice, and analyzed by flow cytometry with species-specific GARP antibody. Mouse GARP was detectable in WT mice and heterozygous B-hGARP. Human GARP was exclusively detectable in heterozygous B-hGARP but not WT mice.